Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Medicinova Inc (MNOV)

Medicinova Inc (MNOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Medicinova Inc 4275 EXECUTIVE SQUARE SUITE 300 LA JOLLA CA 92037 USA

www.medicinova.com P: 858-373-1500 F: 858-404-0048

Description:

MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and twopreclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.

Key Statistics

Overview:

Market Capitalization, $K 72,098
Enterprise Value, $K 21,098
Shares Outstanding, K 49,046
Annual Sales, $ 1,000 K
Annual Net Income, $ -8,570 K
Last Quarter Sales, $ 1,000 K
Last Quarter Net Income, $ -720 K
EBIT, $ -10,640 K
EBITDA, $ -10,620 K
60-Month Beta 0.73
% of Insider Shareholders 16.90%
% of Institutional Shareholders 9.90%
Float, K 40,757
% Float 83.10%
Short Volume Ratio 0.52

Growth:

1-Year Return -32.88%
3-Year Return -71.40%
5-Year Return -85.43%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 52.78%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.04 on 02/15/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -0.19
EPS Growth vs. Prev Qtr -300.00%
EPS Growth vs. Prev Year 33.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MNOV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -13.19%
Return-on-Assets % -12.50%
Profit Margin % -857.00%
Debt/Equity 0.00
Price/Sales 66.70
Price/Cash Flow N/A
Price/Book 1.09
Book Value/Share 1.32
Interest Coverage -0.64
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar